Posted 11 months ago (0 comments)
If you've been diagnosed with thyroid eye disease, you know that the current options leave much to be desired: wait, wait, wait, wait some more -- and eventually get approved for one or more surgeries to address bulging, swelling, and double vision. (With steroid therapy sometimes used as a temporary stopgap). However, the successful trial of a brand new drug could prove to be a game-changer for patients living with this disfiguring and frustrating condition. The New England Journal of Medicine recently published "Teprotumumab for Thyroid-Associated Ophthalmopathy". The authors included GDATF Chief Medical and Scientific Officer Dr. Terry Smith as well as GDATF Physician Advisory Board Members Dr. Raymond Douglas and Dr. George Kahaly. To learn more, please click here for an article from Science Daily or click here to visit Dr. Douglas' Facebook Page.